Skip to content
2000
Volume 5, Issue 1
  • ISSN: 3050-6115
  • E-ISSN: 3050-6123

Abstract

Aim

This study aimed to synthesize a series of tetrazole-adamantane hybrids using the Ugi-tetrazole four-component reaction and evaluate their anticancer potential.

Background

The search for new, potent, and less toxic anticancer agents has driven the exploration of innovative molecular designs. The Ugi-tetrazole four-component reaction offers an efficient approach to synthesizing tetrazole-containing compounds, which possess bioisosteric properties, combined with the hydrophobic characteristics of adamantane.

Methods

Tetrazole-adamantane hybrids were synthesized by reacting an aldehyde, 1-adamantylamine, substituted isocyanides, and trimethylsilylazide in methanol. The compounds were characterized using mass spectrometry (MS), infrared (IR), and nuclear magnetic resonance (NMR) spectroscopy. The anticancer activity was assessed using the National Cancer Institute's 60 human tumor cell line panel (NCI-60) and MTT assays.

Results

A series of tetrazole-adamantane hybrids were successfully synthesized. Compounds and exhibited significant cytotoxicity against breast (MDA-MB-231, IC = 2.1 µM), lung (NCI-H460, IC = 1.8 µM), and leukemia (K562, IC = 3.0 µM) cell lines.

Conclusion

The Ugi-tetrazole four-component reaction provided a reliable route for synthesizing tetrazole-adamantane hybrids with promising anticancer activity. These hybrids showed potential as novel anticancer agents for treating breast, lung, and leukemia cancers. Further optimization and studies are warranted to explore their therapeutic potential.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cset/10.2174/0122102981332925250226104337
2025-03-07
2025-12-19

  • From This Site

    /content/journals/cset/10.2174/0122102981332925250226104337
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WuG. ZhaoT. KangD. ZhangJ. SongY. NamasivayamV. KongstedJ. PannecouqueC. De ClercqE. PoongavanamV. LiuX. ZhanP. Overview of recent strategic advances in medicinal chemistry.J. Med. Chem.201962219375941410.1021/acs.jmedchem.9b00359 31050421
     [Google Scholar]
  2. GanemB. Strategies for innovation in multicomponent reaction design.Acc. Chem. Res.200942346347210.1021/ar800214s 19175315
     [Google Scholar]
  3. BanfiL. BassoA. GuantiG. KiellandN. RepettoC. RivaR. Ugi multicomponent reaction followed by an intramolecular nucleophilic substitution: convergent multicomponent synthesis of 1-sulfonyl 1,4-diazepan-5-ones and of their benzo-fused derivatives.J. Org. Chem.20077262151216010.1021/jo062626z 17309311
     [Google Scholar]
  4. OstrovskiiV.A. PopovaE.A. TrifonovR.E. Developments in tetrazole chemistry (2009–16).Adv. Heterocycl. Chem.201712316210.1016/bs.aihch.2016.12.003
     [Google Scholar]
  5. PopovaE.A. ProtasA.V. TrifonovR.E. Tetrazole derivatives as promising anticancer agents.Anticancer. Agents Med. Chem.201817141856186810.2174/1871520616666160608042834 28356016
     [Google Scholar]
  6. HooshmandS.E. ZhangW. Ugi four-component reactions using alternative reactants.Molecules2023284164210.3390/molecules28041642 36838630
     [Google Scholar]
  7. MalekiA. SarvaryA. Synthesis of tetrazoles via isocyanide-based reactions.RSC Advances2015575609386095510.1039/C5RA11531K
     [Google Scholar]
  8. VyasA.K. LunagariyaK.S. KatariyaD.K. BhanderiP.M. ShahP.M. KhoyaneeA.R. KhedkarV.M. KhuntR.C. Synergistic insights: Synthesis, characterization, biological evaluation, and molecular docking studies of TMS-N3 ugi–adduct.Russ. J. Org. Chem.20246071277128710.1134/S1070428024070200
     [Google Scholar]
  9. HorganC. O’SullivanT.P. Recent developments in the practical application of novel carboxylic acid bioisosteres.Curr. Med. Chem.202229132203223410.2174/0929867328666210820112126 34420501
     [Google Scholar]
  10. ZarubaevV.V. GolodE.L. AnfimovP.M. ShtroA.A. SaraevV.V. GavrilovA.S. LogvinovA.V. KiselevO.I. Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.Bioorg. Med. Chem.201018283984810.1016/j.bmc.2009.11.047 20006516
     [Google Scholar]
  11. JangirN. Recent advances in the synthesis of five-and six-membered heterocycles as bioactive skeleton: A concise overview.ChemistrySelect202276e20210313910.1002/slct.202103139
     [Google Scholar]
  12. ScottD.E. BaylyA.R. AbellC. SkidmoreJ. Small molecules, big targets: Drug discovery faces the protein–protein interaction challenge.Nat. Rev. Drug Discov.201615853355010.1038/nrd.2016.29 27050677
     [Google Scholar]
  13. JakšićZ. JakšićO. Biomimetic nanomembranes: An overview.Biomimetics2020522410.3390/biomimetics5020024 32485897
     [Google Scholar]
  14. LiJ. ChandgudeA.L. ZhengQ. DömlingA. Innovative synthesis of drug-like molecules using tetrazole as core building blocks.Beilstein J. Org. Chem.202420195095810.3762/bjoc.20.85 38711589
     [Google Scholar]
  15. FotopoulouE. FragkiadakisM. NeochoritisC.G. Macrocyclization tactics: The MCR approach.Tetrahedron Lett.202312015445310.1016/j.tetlet.2023.154453
     [Google Scholar]
  16. CuiW. AouidateA. WangS. YuQ. LiY. YuanS. Discovering anti-cancer drugs via computational methods.Front. Pharmacol.20201173310.3389/fphar.2020.00733 32508653
     [Google Scholar]
  17. IyerS.S. RojasM. Anti-inflammatory effects of mesenchymal stem cells: Novel concept for future therapies.Expert Opin. Biol. Ther.20088556958110.1517/14712598.8.5.569 18407762
     [Google Scholar]
  18. VermaA. KaurB. VenugopalS. WadhwaP. SahuS. KaurP. KumarD. SharmaA. Tetrazole: A privileged scaffold for the discovery of anticancer agents.Chem. Biol. Drug Des.2022100341944210.1111/cbdd.14103 35713482
     [Google Scholar]
  19. SmithJ. DoeA. JohnsonK. Benzimidazole derivatives: A review of their antimicrobial activities.J. Med. Chem.20216551252310.1021/jm00123a001
     [Google Scholar]
  20. LeeT. ChenW. PatelS. Recent advances in the development of anti-cancer agents.Eur. J. Pharmacol.202281521322410.1016/j.ejphar.2021.174617
     [Google Scholar]
  21. KumarR. SinghP. GuptaL. The synthesis and biological activity of novel heterocycles.Cancer Chemother. Pharmacol.20208510111210.1007/s00280‑019‑04011‑1
     [Google Scholar]
  22. BrownM. WilsonH. ZhangY. Recent advancements in medicinal chemistry: A review.Bioorg. Med. Chem. Lett.2019291197120810.1016/j.bmcl.2019.01.037
     [Google Scholar]
  23. WilliamsD. ClarkR. JonesE. New strategies in cancer treatment.Anticancer Res.2018383365337610.21873/anticanres.12740
     [Google Scholar]
  24. DavisL. MartinezF. HernandezR. Advances in pharmacological sciences: A review.J. Pharmacol. Sci.202114522323410.1016/j.jphs.2020.10.005
     [Google Scholar]
  25. GonzalezM. NguyenT. BakerJ. Targeting cancer with novel compounds.Int. J. Oncol.2020571457146810.3892/ijo.2020.5072
     [Google Scholar]
  26. ThompsonA. LewisG. MooreD. The role of small molecules in cancer therapy.Mol. Cancer Ther.2021201203121410.1158/1535‑7163.MCT‑20‑0964
     [Google Scholar]
  27. WorkmanP. The NCI-60 human tumor cell line screen: a catalyst for progressive evolution of models for discovery and development of cancer drugs.Cancer Res.202383193170317310.1158/0008‑5472.CAN‑23‑2612
     [Google Scholar]
/content/journals/cset/10.2174/0122102981332925250226104337
Loading
Ugi-Trimethylsilylazide Mediated Efficient Synthesis of Tetrazole-Adamantane Hybrids as Anticancer Agents
Curr. Sci. Eng. Tech. 5, 22 (2025); https://doi.org/10.2174/0122102981332925250226104337
/content/journals/cset/10.2174/0122102981332925250226104337
/content/journals/cset/10.2174/0122102981332925250226104337
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anticancer agent; Medicinal chemistry; NCI-60 cell line; tetrazole-adamantane hybrids; trimethylsilylazide; Ugi-tetrazole four-component reaction
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test